Irene Campi1,2, Luigi Gennari3, Gianfranco Parati4,5, Luca Persani1,6, Daniela Merlotti3, Christian Mingiano3, Alessandro Frosali3, Luca Giovanelli1,6, Camilla Torlasco4,5, Martino F Pengo4,5, Francesca Heilbron4,5, Davide Soranna7, Antonella Zambon7,8, Marta Di Stefano1,6, Carmen Aresta1,6, Marco Bonomi1,6, Biagio Cangiano1,6, Vittoria Favero1,6, Letizia Fatti1,6, Giovanni Battista Perego4, Iacopo Chiodini9,10. 1. Department of Endocrine and Metabolic Diseases & Lab of Endocrine and Metabolic Research, IRCCS, Istituto Auxologico Italiano, Via Magnasco 2, 20149, Milan, Italy. 2. Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. 3. Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy. 4. Department of Cardiovascular, Neural and Metabolic Sciences, IRCCS, Istituto Auxologico Italiano, Milan, Italy. 5. Department of Medicine and Surgery, University of Milano-Bicocca, 20100, Milan, Italy. 6. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. 7. Biostatistic Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy. 8. Department of Statistics and Quantitative Methods, Università di Milano-Bicocca, Milan, Italy. 9. Department of Endocrine and Metabolic Diseases & Lab of Endocrine and Metabolic Research, IRCCS, Istituto Auxologico Italiano, Via Magnasco 2, 20149, Milan, Italy. iacopo.chiodini@unimi.it. 10. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. iacopo.chiodini@unimi.it.
Abstract
BACKGROUND: Vitamin D deficiency has been suggested to favor a poorer outcome of Coronavirus disease-19 (COVID-19). We aimed to assess if 25-hydroxyvitamin-D (25OHD) levels are associated with interleukin 6 (IL-6) levels and with disease severity and mortality in COVID-19. METHODS: We prospectively studied 103 in-patients admitted to a Northern-Italian hospital (age 66.1 ± 14.1 years, 70 males) for severely-symptomatic COVID-19. Fifty-two subjects with SARS-CoV-2 infection but mild COVID-19 symptoms (mildly-symptomatic COVID-19 patients) and 206 subjects without SARS-CoV-2 infection were controls. We measured 25OHD and IL-6 levels at admission and focused on respiratory outcome during hospitalization. RESULTS: Severely-symptomatic COVID-19 patients had lower 25OHD levels (18.2 ± 11.4 ng/mL) than mildly-symptomatic COVID-19 patients and non-SARS-CoV-2-infected controls (30.3 ± 8.5 ng/mL and 25.4 ± 9.4 ng/mL, respectively, p < 0.0001 for both comparisons). 25OHD and IL-6 levels were respectively lower and higher in severely-symptomatic COVID-19 patients admitted to intensive care Unit [(ICU), 14.4 ± 8.6 ng/mL and 43.0 (19.0-56.0) pg/mL, respectively], than in those not requiring ICU admission [22.4 ± 1.4 ng/mL, p = 0.0001 and 16.0 (8.0-32.0) pg/mL, p = 0.0002, respectively]. Similar differences were found when comparing COVID-19 patients who died in hospital [13.2 ± 6.4 ng/mL and 45.0 (28.0-99.0) pg/mL] with survivors [19.3 ± 12.0 ng/mL, p = 0.035 and 21.0 (10.5-45.9) pg/mL, p = 0.018, respectively). 25OHD levels inversely correlated with: i) IL-6 levels (ρ - 0.284, p = 0.004); ii) the subsequent need of the ICU admission [relative risk, RR 0.99, 95% confidence interval (95%CI) 0.98-1.00, p = 0.011] regardless of age, gender, presence of at least 1 comorbidity among obesity, diabetes, arterial hypertension, creatinine, IL-6 and lactate dehydrogenase levels, neutrophil cells, lymphocytes and platelets count; iii) mortality (RR 0.97, 95%CI, 0.95-0.99, p = 0.011) regardless of age, gender, presence of diabetes, IL-6 and C-reactive protein and lactate dehydrogenase levels, neutrophil cells, lymphocytes and platelets count. CONCLUSION: In our COVID-19 patients, low 25OHD levels were inversely correlated with high IL-6 levels and were independent predictors of COVID-19 severity and mortality.
BACKGROUND:Vitamin D deficiency has been suggested to favor a poorer outcome of Coronavirus disease-19 (COVID-19). We aimed to assess if 25-hydroxyvitamin-D (25OHD) levels are associated with interleukin 6 (IL-6) levels and with disease severity and mortality in COVID-19. METHODS: We prospectively studied 103 in-patients admitted to a Northern-Italian hospital (age 66.1 ± 14.1 years, 70 males) for severely-symptomatic COVID-19. Fifty-two subjects with SARS-CoV-2 infection but mild COVID-19 symptoms (mildly-symptomatic COVID-19patients) and 206 subjects without SARS-CoV-2 infection were controls. We measured 25OHD and IL-6 levels at admission and focused on respiratory outcome during hospitalization. RESULTS: Severely-symptomatic COVID-19patients had lower 25OHD levels (18.2 ± 11.4 ng/mL) than mildly-symptomatic COVID-19patients and non-SARS-CoV-2-infected controls (30.3 ± 8.5 ng/mL and 25.4 ± 9.4 ng/mL, respectively, p < 0.0001 for both comparisons). 25OHD and IL-6 levels were respectively lower and higher in severely-symptomatic COVID-19patients admitted to intensive care Unit [(ICU), 14.4 ± 8.6 ng/mL and 43.0 (19.0-56.0) pg/mL, respectively], than in those not requiring ICU admission [22.4 ± 1.4 ng/mL, p = 0.0001 and 16.0 (8.0-32.0) pg/mL, p = 0.0002, respectively]. Similar differences were found when comparing COVID-19patients who died in hospital [13.2 ± 6.4 ng/mL and 45.0 (28.0-99.0) pg/mL] with survivors [19.3 ± 12.0 ng/mL, p = 0.035 and 21.0 (10.5-45.9) pg/mL, p = 0.018, respectively). 25OHD levels inversely correlated with: i) IL-6 levels (ρ - 0.284, p = 0.004); ii) the subsequent need of the ICU admission [relative risk, RR 0.99, 95% confidence interval (95%CI) 0.98-1.00, p = 0.011] regardless of age, gender, presence of at least 1 comorbidity among obesity, diabetes, arterial hypertension, creatinine, IL-6 and lactate dehydrogenase levels, neutrophil cells, lymphocytes and platelets count; iii) mortality (RR 0.97, 95%CI, 0.95-0.99, p = 0.011) regardless of age, gender, presence of diabetes, IL-6 and C-reactive protein and lactate dehydrogenase levels, neutrophil cells, lymphocytes and platelets count. CONCLUSION: In our COVID-19patients, low 25OHD levels were inversely correlated with high IL-6 levels and were independent predictors of COVID-19 severity and mortality.
Entities:
Keywords:
COVID-19; Interleukin-6; Mortality; Vitamin D
Authors: Fiona Havers; Laura Smeaton; Nikhil Gupte; Barbara Detrick; Robert C Bollinger; James Hakim; Nagalingeswaran Kumarasamy; Adriana Andrade; Parul Christian; Javier R Lama; Thomas B Campbell; Amita Gupta Journal: J Infect Dis Date: 2014-05-05 Impact factor: 5.226
Authors: Roger Bouillon; Claudio Marcocci; Geert Carmeliet; Daniel Bikle; John H White; Bess Dawson-Hughes; Paul Lips; Craig F Munns; Marise Lazaretti-Castro; Andrea Giustina; John Bilezikian Journal: Endocr Rev Date: 2019-08-01 Impact factor: 19.871
Authors: Matthew J Cummings; Matthew R Baldwin; Darryl Abrams; Samuel D Jacobson; Benjamin J Meyer; Elizabeth M Balough; Justin G Aaron; Jan Claassen; LeRoy E Rabbani; Jonathan Hastie; Beth R Hochman; John Salazar-Schicchi; Natalie H Yip; Daniel Brodie; Max R O'Donnell Journal: Lancet Date: 2020-05-19 Impact factor: 79.321
Authors: Puja Mehta; Daniel F McAuley; Michael Brown; Emilie Sanchez; Rachel S Tattersall; Jessica J Manson Journal: Lancet Date: 2020-03-16 Impact factor: 79.321
Authors: Adrian Matysek; Aneta Studnicka; Wade Menpes Smith; Michał Hutny; Paweł Gajewski; Krzysztof J Filipiak; Jorming Goh; Guang Yang Journal: Front Med (Lausanne) Date: 2022-08-01
Authors: Juraj Smaha; Martin Kužma; Peter Jackuliak; Samuel Nachtmann; Filip Max; Elena Tibenská; Neil Binkley; Juraj Payer Journal: Nutrients Date: 2022-06-07 Impact factor: 6.706
Authors: F Coperchini; A Greco; M Denegri; F A Ripepi; B Grillini; J Bertini; B Calì; L Villani; F Magri; L Croce; C Gaetano; C Cappelli; P Trimboli; L Chiovato; M Rotondi Journal: J Endocrinol Invest Date: 2022-07-12 Impact factor: 5.467
Authors: Leszek Tylicki; Ewelina Puchalska-Reglińska; Piotr Tylicki; Aleksander Och; Karolina Polewska; Bogdan Biedunkiewicz; Aleksandra Parczewska; Krzysztof Szabat; Jacek Wolf; Alicja Dębska-Ślizień Journal: J Clin Med Date: 2022-01-06 Impact factor: 4.241